انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
المدونة الصوتية تستحق الاستماع
برعاية
CAR T therapies: Engineering immune cells to treat cancer
Manage episode 357984997 series 3291201
Featuring:
Dr. Joerg Krueger, Medical Director, CAR T-Cell Program, The Hospital for Sick Children.
Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine.
Our guests discuss the future of CAR T-cell therapies, in a conversation covering autologous and allogeneic CAR T therapies. Drs. Krueger and Levine share their thoughts on which of these two approaches is likely to pull ahead in the years to come, while acknowledging some of the challenges that will need to be overcome for each, including donor-to-donor variability. Also examined are the differences in adult and pediatric treatment options, along with the complexity involved in manufacturing CAR T cells. Recent advances in the area of solid tumours are highlighted, ending on a note that looks to the future of immunotherapy with warranted optimism.
Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.
21 حلقات
Manage episode 357984997 series 3291201
Featuring:
Dr. Joerg Krueger, Medical Director, CAR T-Cell Program, The Hospital for Sick Children.
Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine.
Our guests discuss the future of CAR T-cell therapies, in a conversation covering autologous and allogeneic CAR T therapies. Drs. Krueger and Levine share their thoughts on which of these two approaches is likely to pull ahead in the years to come, while acknowledging some of the challenges that will need to be overcome for each, including donor-to-donor variability. Also examined are the differences in adult and pediatric treatment options, along with the complexity involved in manufacturing CAR T cells. Recent advances in the area of solid tumours are highlighted, ending on a note that looks to the future of immunotherapy with warranted optimism.
Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.
21 حلقات
كل الحلقات
×![Artwork](/static/images/128pixel.png)
1 Enabling patient access to cell and gene therapies 28:20
![Artwork](/static/images/128pixel.png)
1 Unapproved stem cell therapies: Risks, realities and responsibilities 35:30
![Artwork](/static/images/128pixel.png)
1 Biomanufacturing redefined: The role of AI and robotics in producing cell and gene therapies 34:59
![Artwork](/static/images/128pixel.png)
1 Expert insights for taking a cell or gene therapy company from vision to reality 26:25
![Artwork](/static/images/128pixel.png)
1 Regulators' strategies for managing the surge in cell and gene therapies 27:35
![Artwork](/static/images/128pixel.png)
1 How Creative Destruction Lab accelerates the advanced therapies industry 24:23
![Artwork](/static/images/128pixel.png)
1 The synergy solution: How public-private partnerships advance regenerative medicine 34:43
![Artwork](/static/images/128pixel.png)
1 Catalysts of change: Canada’s research hubs are shaping the future of biomanufacturing 33:24
![Artwork](/static/images/128pixel.png)
1 From code to cure: Exploring the synergies of artificial intelligence and regenerative medicine 33:23
![Artwork](/static/images/128pixel.png)
1 Stuck in the sixties: The fight to fast-forward access to better cancer treatment 27:24
![Artwork](/static/images/128pixel.png)
1 CAR T therapies: Engineering immune cells to treat cancer 31:10
![Artwork](/static/images/128pixel.png)
1 Protecting the product of innovation: IP and commercialization in cell and gene therapies 34:23
![Artwork](/static/images/128pixel.png)
1 Mentoring: making moves to maximize career growth 27:53
![Artwork](/static/images/128pixel.png)
1 Unlocking the potential of induced pluripotent stem cells 27:31
![Artwork](/static/images/128pixel.png)
1 Training tomorrow’s talent: building the biomanufacturing workforce 23:05
مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.